Overview of Flogocid

Quick Facts about Flogocid

Property	Description
Active Ingredients	Bufexamac, Neomycin, Nystatin
Form	Topical cream or ointment
Pharmacological Class	Combination Dermatological Preparation
Route of Administration	Cutaneous (Topical)
Composition Type	Triple-active combination product

Flogocid is a specialized triple-active combination pharmaceutical preparation for topical use, specifically formulated to address complex skin inflammation complicated by microbial infections. Its core identity is defined by the simultaneous application of three distinct active components, each designed to address a different aspect of the skin pathology. This combination is recognized for its comprehensive action in managing inflamed and secondarily infected skin.

What Type of Medicine is Flogocid and What is its Composition?

Flogocid is classified as a Combination Dermatological Preparation because it integrates three active components, each belonging to a separate therapeutic class. The non-steroidal anti-inflammatory ingredient, Bufexamac, is characterized as a Non-steroidal Anti-inflammatory Drug (NSAID). This allows the medication to help reduce local irritation without the use of corticosteroids. The antibacterial agent, Neomycin, is an aminoglycoside antibiotic, derived from natural sources, which is recognized for its effectiveness against common bacterial skin pathogens. Completing the combination is Nystatin, which is a polyene antifungal medication primarily targeting yeasts, such as those in the Candida genus. The resulting formulation is a fixed semi-synthetic/derived combination.

Flogocid’s Dual Purpose and Available Forms

The general purpose of Flogocid is the comprehensive, localized management of skin irritation by concurrently reducing inflammation and targeting susceptible bacterial and fungal microorganisms. This fixed composition is specifically positioned for situations like managing inflamed eczema that has developed signs of secondary infection. The formulation provides a dual anti-infective and anti-inflammatory action based on the properties of its components. Flogocid is available for cutaneous administration in two main dosage forms: a topical cream utilizing an emulsion base, and a topical ointment which employs a more occlusive lipophilic base, allowing the medication to be matched to the specific physical state of the skin lesion.

What side effects are possible with Flogocid?

Possible side effects and safety information

The safety profile for Flogocid, a combination topical preparation, is formally documented by regulatory authorities, focusing on both local reactions and the potential for systemic effects from its components.

Adverse Reaction Scope

The most frequently observed adverse reactions are localized skin and subcutaneous tissue disorders. These often include irritation, burning sensation, redness (erythema), and itching (pruritus) at the site of application. A less common but clinically significant reaction is allergic contact dermatitis, which has been notably associated with the Bufexamac component and can sometimes be severe.

Systemic and Serious Safety Considerations

The Neomycin component introduces risks for systemic toxicity if absorbed in high amounts, particularly when the cream is applied to large areas of broken or damaged skin. The most serious adverse reactions documented in regulatory sources related to systemic absorption include Irreversible Ototoxicity (hearing damage) and Nephrotoxicity (kidney damage). These severe effects are classified as rare, but their risk is explicitly noted to increase with prolonged duration of use.

Population-Specific Safety Notes

Official labeling identifies specific populations with a heightened risk of systemic adverse effects. These include patients with pre-existing impaired renal function, who may clear absorbed Neomycin more slowly, and infants and young children due to their higher skin-surface-area-to-body-weight ratio. The medicine is formally contraindicated in individuals with a known history of hypersensitivity to any of the active components, including cross-sensitivity to other aminoglycoside antibiotics.

This profile defines the medicine's safety limits, distinguishing between common, localized irritation and rare, serious systemic risks linked to the potential for antibiotic absorption under specific, high-risk conditions.

Overdose and Emergency Response

The official regulatory description of Flogocid overdose is defined by the risks associated with systemic absorption, which occurs primarily after accidental oral ingestion or excessive topical use over large or compromised skin areas. Documented presentations of overdose from the Bufexamac component may involve gastrointestinal and central nervous system effects, such as nausea, vomiting, lethargy, and confusion.

The most severe documented outcomes are linked to the systemic absorption of the Neomycin component, which may lead to nephrotoxicity (kidney damage) and neurotoxicity, including the risk of permanent bilateral auditory ototoxicity (hearing loss). Patients with impaired renal function and specific populations such as neonates and premature infants are officially noted as being at increased risk for these severe toxicities in an overdose situation.

Immediate medical attention is required for any suspected overdose, accidental ingestion, or the onset of severe symptoms like convulsions or signs of serious allergic reaction. Regulatory documents confirm that no specific antidote is known for this combination overdose. Management is officially described as symptomatic and supportive care, which includes the need for close clinical observation and monitoring of renal function tests to track potential Neomycin toxicity.

Therapeutic Uses of Flogocid

Quick Facts

Relief from inflamed skin conditions: Helps manage the swelling, redness, and itching associated with various skin irritations.
Treatment for mixed skin infections: Contains agents to address co-occurring bacterial and fungal skin infections.
Aid for dermatological issues: Used to treat conditions such as dermatitis, eczema, and psoriasis.

What Flogocid Treats: Main Uses and Benefits

Flogocid cream is utilized to treat a range of inflammatory skin conditions that may be complicated by secondary infection. Its therapeutic application is primarily focused on alleviating the characteristic symptoms of skin irritation.

The medication is used for relief of inflammation and associated itching and redness in dermatological disorders such as eczema, various forms of dermatitis (including atopic and contact types), and psoriasis. It is also indicated for managing infected inflammatory processes like ulcers, pimples, and certain stages of bedsores.

A key benefit is its combined action. It addresses the signs of inflammation while simultaneously working to counter co-existing microbial issues. Due to the inclusion of an antibiotic and an antifungal component, Flogocid can effectively treat and prevent the spread of bacterial and fungal skin infections that often accompany primary inflammatory conditions. This dual action supports skin healing and revitalization.

Eligibility and Restrictions for Use

The eligibility profile for Flogocid, including specific regulatory constraints and formal contraindications, is not detailed within the major authoritative government regulatory documents from agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Flogocid is typically marketed in certain regions as a cream containing a combination of active ingredients, which may include components like an antibiotic (e.g., Neomycin), an antifungal (e.g., Nystatin), and an anti-inflammatory agent (e.g., Bufexamac or Fluocinolone Acetonide). While official, government-approved labeling for the specific Flogocid combination product is not publicly available in these major databases, eligibility rules are generally determined by the known profile of its individual components.

Official Eligibility Constraints

Category	Regulatory Status (Flogocid Combination)
Populations with Contraindicated Use	Formal contraindications for the specific Flogocid combination are not established in official sources searched.
Age-Group Restrictions	Age-related eligibility rules (e.g., use in infants or children) are not defined in official sources for this product.
Physiological States	Eligibility during pregnancy and lactation is not explicitly documented as an official regulatory status.

Eligibility for use is typically subject to a medical professional's assessment of individual factors, particularly a patient's known sensitivities or allergies to any of the specific ingredients in the preparation. The lack of a verified regulatory monograph prevents the formal listing of official exclusions, restrictions, or special considerations based on comorbidities like hepatic or renal impairment.

What should I know about interactions with other medicines?

Flogocid Interactions with other medicines and products

Official regulatory information for Flogocid, a topical combination product containing Bufexamac, Neomycin, and Nystatin, focuses on potential interactions arising from the systemic exposure of its active components when the medication is applied to compromised or large areas of skin.

Documented Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Substance/Class	Official Caution Context
Additive Pharmacodynamic Risk	Systemic Non-Steroidal Anti-inflammatory Drugs (NSAIDs)	The Bufexamac component may contribute to the potential for increased NSAID-class systemic adverse effects.
Additive Systemic Toxicity	Systemic Aminoglycoside Antibiotics	The Neomycin component carries a risk of contributing to additive ototoxicity and nephrotoxicity if absorbed systemically.

Interaction Constraints and Considerations

Official documentation does not cite any specific medicinal product combinations that are formally classified as contraindicated solely due to drug-drug interaction risk for this topical product. Furthermore, no mandatory time separation rules are specified for co-administered medicines.

Population-Specific Caution

Official prescribing information notes that patients with pre-existing kidney disease may be at a heightened risk of the systemic consequences (nephrotoxicity) resulting from the potential absorption of the Neomycin component. This is a crucial consideration when the topical product is used on damaged skin or over extensive body surface areas.

Regulatory documents emphasize that the clinical relevance of these interactions is directly proportional to the amount of active ingredient absorbed into the body, which is primarily influenced by the integrity and extent of the treated skin area.

Mechanism of Action

How Flogocid Works: Mechanism of Action

Inhibiting Key Inflammatory Pathways

This action is primarily driven by bufexamac, which works by directly inhibiting the cyclooxygenase (COX) enzyme in the affected tissue. Blocking this specific enzyme prevents the cellular machinery from producing pro-inflammatory chemical mediators like prostaglandins, resulting in a state of lowered tissue edema and decreased activation of nociceptive pathways.

Targeting Microbial Cell Integrity

The drug exerts its anti-microbial effect through two distinct mechanisms. Nystatin acts on fungal cell membranes by binding to sterols, thereby creating pores that destroy the structural integrity of the cell, leading to the loss of osmotic stability and subsequent cell lysis. Concurrently, neomycin acts on bacteria by interfering with the 30S ribosomal subunit, which halts the production of essential bacterial proteins, thereby interfering with the biological processes required for bacterial maintenance and proliferation.

Synergistic Mechanistic Actions

These three distinct actions—enzyme inhibition, fungal membrane disruption, and bacterial protein synthesis interference—occur simultaneously at the site of application. The combination produces three distinct mechanistic actions that together modulate cellular responses.

Dosage and Administration Information

How to Use Flogocid: Administration Guidelines

The usage of the triple-active combination preparation Flogocid follows specific application principles based on its components. This section details the administration route, dosing schedule, duration, and key procedural constraints.

Application Scope and Frequency

Flogocid is administered via the cutaneous route (topical use) as a cream or ointment. The application schedule is generally twice daily, which may be adjusted to a higher frequency as directed by a healthcare professional. The dosing principle involves applying a thin layer sufficient to cover the affected area and the periphery of the lesion.

Instruction	Guideline
Route of Administration	Cutaneous (Topical) only, avoiding eyes and mucous membranes.
Standard Frequency	Twice daily, or as prescribed up to three times daily.
Dose Principle	Apply a thin layer to the affected area.

Procedural and Duration Requirements

The treatment site should be cleansed and dried prior to application to ensure proper adherence. A key administration constraint is that the treated area must not be covered with an occlusive dressing (airtight bandage) unless specific instruction is provided. Use is established for the pediatric population from birth onward.

Therapy is intended to continue until the full prescribed course is completed, which is necessary for resolving co-existing microbial issues, even if symptomatic improvement occurs earlier. If a scheduled application is missed, the dose is typically skipped if it is nearly time for the next application, and doses must not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flogocid

Evidence for Use in Inflamed Dermatoses with Suspected Secondary Infection

Research examined this combination product in contexts involving conditions characterized by fluctuating or episodic manifestations, such as eczema and dermatitis, where a secondary microbial infection was suspected. Research examined the combined use of the anti-inflammatory, antibacterial, and antifungal components in Randomized Controlled Trials (RCTs) and various clinical trials. These studies were conducted during periods of increased symptom activity and were used to evaluate outcomes related to physical discomfort and inflammatory or irritative states.

Studies primarily monitored short-term patterns in populations of adults and children. These trials reported measurements related to symptoms over follow-up durations that were typically limited to two to eight weeks. Findings describe patterns observed in the studies, such as reports related to redness, itching, and swelling, and data collected to monitor microbiological pathogen reduction.

Research on the Anti-inflammatory Component (Bufexamac)

The non-steroidal anti-inflammatory component, Bufexamac, was studied for use in various inflammatory skin conditions. The evidence base includes older clinical trials and regulatory reviews that have assessed the available data. Research examined outcomes linked to inflammatory or irritative states, such as the reported change in redness and intense itching. In reviewing the total evidence, regulatory evaluations in some regions have indicated that the data for the component’s standalone performance is limited.

Studies on the Anti-Infective Components (Neomycin and Nystatin)

Research for the antifungal agent, Nystatin, includes Systematic Reviews and Meta-analyses that explored its use against cutaneous yeast infections. The evidence base for Nystatin generally appears to be more extensive, with research describing its role in treating cutaneous yeast infections. Similarly, the antibacterial agent Neomycin was observed in trials, often as part of combination products, that monitored bacteriological response and clinical symptom patterns for infected skin lesions. However, comparative evidence against newer antibiotics is sometimes lacking.

What is Still Uncertain About Flogocid Research

The current scientific literature highlights several key areas where certainty remains low. A core limitation is the modest sample sizes and the age of many of the clinical studies specifically examining the Bufexamac/Neomycin/Nystatin combination. Long-term effects are not fully established, and comparative evidence is lacking against many modern, alternative treatments.

Key Studies & References Bufexamac - Therapeutic Goods Administration (TGA) Safety Advisory

Frequently Asked Questions (FAQ)

Common questions about Flogocid (FAQ)

Q: Can Flogocid be taken with pain relievers like ibuprofen?

Official warnings related to the Neomycin component advise caution when the product is used alongside certain pain or arthritis medicines, such as Non-Steroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. The concern described is the possibility of increased potential for effects on the kidneys due to systemic absorption of the antibiotic component.

Q: Are there any long-term safety concerns with using Flogocid?

Regulatory information for the Neomycin component notes that the risk of serious side effects, such as permanent hearing damage (ototoxicity), is associated with long-term use or high systemic doses. For this reason, official regulatory documentation generally describes prolonged or continuous use of the preparation as carrying a heightened risk.

Q: Does Flogocid interact with birth control pills?

The Neomycin component belongs to a class of antibiotics for which regulatory documents note a potential for interaction with hormonal contraceptives. The documented concern is that this interaction carries a potential for reduced effectiveness of the contraceptive.

Q: Can Flogocid affect the liver or kidneys?

Official warnings for the Neomycin component focus primarily on the risk of potential nephrotoxicity (kidney damage) if the medicine is absorbed systemically. The potential for this risk is influenced by the integrity and extent of the treated skin area. The warnings focus on the potential for nephrotoxicity (kidney damage).

Q: Can I use Flogocid if I have a history of allergies?

Official regulatory information states that the medicine is contraindicated (should not be used) in individuals with a known history of hypersensitivity or allergy to any of its active components. Allergic contact dermatitis has been notably associated with the Bufexamac component.

Q: Is it okay to use Flogocid if I am breastfeeding?

Regulatory documents state that it is unknown if the Nystatin component is excreted in human milk. Therefore, official advice states that the use of Flogocid in a nursing woman should be determined by a healthcare provider after carefully considering the potential benefits versus the risks.

Q: What are the main risks associated with Flogocid, according to regulators?

The frequently observed reactions are localized skin reactions, such as a burning sensation, irritation, and allergic contact dermatitis. Less common but serious risks, linked to the potential systemic absorption of Neomycin, include ototoxicity (hearing damage) and nephrotoxicity (kidney damage), especially with use on large or broken skin areas.

Q: Is Flogocid safe to use during pregnancy?

The Nystatin component is assigned a US FDA Pregnancy Category C. This indicates that animal studies have shown an adverse effect on the fetus, and there are no adequate studies in humans. The official documentation indicates that the product should only be used when the prescribing professional has determined the potential benefit to outweigh the potential risk.

Q: Can Flogocid cause fatigue or drowsiness?

Official lists of adverse reactions for the topical components of Flogocid do not commonly include fatigue or drowsiness as directly reported systemic side effects.

Q: Is Flogocid appropriate for children?

Regulatory documents state that safety and effectiveness for the Nystatin component have been established for use in the pediatric population from birth to 16 years of age. Infants and young children are listed as a population with a heightened potential for systemic adverse effects due to their higher skin absorption rate.

Q: Is Flogocid considered a steroid?

No. Flogocid is a Combination Dermatological Preparation containing three distinct components: an antifungal (Nystatin), an antibiotic (Neomycin), and the anti-inflammatory component Bufexamac, which is a Non-Steroidal Anti-inflammatory Drug (NSAID). The preparation does not contain any steroids.

Q: Is there a maximum time someone should use Flogocid?

A regulatory warning notes that using the cream or ointment for more than 14 days may increase the risk of the bacteria becoming resistant to the antibiotic component (Neomycin). Prolonged use is described in official documentation as carrying a risk of increasing systemic absorption of the Neomycin component.

Q: What is the general safety classification for Flogocid?

The Nystatin component is assigned a US FDA Pregnancy Category C. This is a classification used to describe medications where the potential for risk cannot be ruled out, and use during pregnancy must be carefully weighed against the potential benefit.

Q: Does Flogocid need to be refrigerated?

Official product information describes that the product should typically be stored at room temperature. This is generally defined as between 68 F to 77 F (20, C to 25, C). No specific refrigeration is required for standard storage.

Q: Why is Flogocid not recommended for certain age groups?

Regulatory documents highlight that infants and young children are at a heightened risk of potential systemic side effects from the Neomycin component. This is due to their higher skin-surface-area-to-body-weight ratio, which increases the potential for systemic absorption of the antibiotic into the bloodstream.

Q: What should I do if Flogocid doesn't seem to be working?

Regulatory precautions state that if there is a lack of therapeutic response after a period of use, diagnostic methods such as cultures or smears should be repeated by a healthcare provider. This is done to monitor the therapeutic response and microbiological pathogen reduction.

Q: What if I accidentally use more Flogocid than intended?

Official documents on the Nystatin component note that there have been no reports of serious toxic effects following overdosage. However, excessive use over large or broken skin areas may increase the potential for systemic absorption of the Neomycin component, increasing the risk of associated side effects.

Q: Is Flogocid available over-the-counter or only with a prescription?

Official product information for the combination preparation generally indicates that the medicine requires a prescription for dispensing. This classification is due to the presence of an antibiotic and other active pharmacological ingredients.

Q: Is it normal to feel a mild burning sensation when using Flogocid?

Yes, official documentation describes that common local adverse reactions can include a burning sensation, irritation, and itching at the site of application. These reactions are typically localized and are considered frequently observed side effects of the topical treatment.

How should Flogocid be stored and disposed of?

How to Store and Dispose of Flogocid? — Official Regulatory Information

Official regulatory documents from major health agencies do not specify product-specific storage temperature or stability requirements for Flogocid. The focus is on ensuring safe and proper disposal when the medicine is unused or expired.

Storage & Disposal Scope	Official Requirement or Regulatory Standard
Product-Specific Storage	No product-specific temperature, light, or moisture requirements found in official documents.
Priority Disposal Method	The safest disposal method is using an authorized medicine take-back program, such as local drug disposal kiosks or mail-back envelopes.
Household Trash Protocol	If a take-back option is unavailable, the medicine must be rendered unusable by mixing it with an undesirable substance (like dirt or used coffee grounds).
Waste Containment	The modified drug mixture must be placed inside a sealed bag or container before being discarded into household trash.
Privacy Protection	All personal information must be removed or scratched out from the prescription label and container prior to disposal.

Flogocid